


Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

This announcement is for information purposes only and does not constitute an invitation or solicitation of an offer to acquire, purchase or subscribe for securities or an invitation to enter into an agreement to do any such things, nor is it calculated to invite any offer to acquire, purchase or subscribe for any securities.

*This announcement is not for distribution, directly or indirectly, in or into the United States (including its territories and possessions, any state of the United States and the District of Columbia). This announcement and the information herein do not constitute or form a part of any offer or solicitation to purchase, subscribe or sell securities in the United States. The securities referred to herein have not been and will not be registered under the United States Securities Act of 1933, as amended (the “**Securities Act**”), or the securities laws of any state of the United States or other jurisdiction. The securities referred to herein will be offered and sold outside the United States in reliance on Regulation S under the Securities Act and may not be offered or sold within the United States absent registration or an applicable exemption from registration under the Securities Act. No public offering of the securities referred to herein is being or will be made in the United States or in any other jurisdiction where such an offering is restricted or prohibited. No money, securities or other consideration is being solicited by this announcement or the information contained herein and, if sent in response to this announcement or the information contained herein, will not be accepted.*



Horizon Robotics

*(A company controlled through weighted voting rights and incorporated in the Cayman Islands with limited liability)
(Stock Code: 9660)*

COMPLETION OF THE ISSUE OF US\$450,000,000 ZERO COUPON CONVERTIBLE BONDS DUE 2027

Joint Global Coordinators and Joint Bookrunners

GOLDMAN SACHS (ASIA) L.L.C.

MORGAN STANLEY ASIA LIMITED

References are made to the announcement of the Company on July 22, 2026 in relation to the amendment of a convertible loan agreement, the announcement of the Company on July 22, 2026 in relation to the proposed issue of Convertible Bonds under General Mandate and the announcement of the Company on July 23, 2026 in relation to the pricing of US\$450,000,000 zero coupon Convertible Bonds due 2027 (collectively, the “**Announcements**”). Unless otherwise defined in this announcement, capitalized terms used herein shall have the same meanings as defined in the Announcements.

COMPLETION OF THE ISSUE OF THE BONDS

The Board is pleased to announce that all the conditions precedent under the Subscription Agreement have been fulfilled and the issue of the Bonds in an aggregate principal amount of US\$450,000,000 was completed on July 29, 2026.

The aggregate gross proceeds from the issue of the Bonds are approximately US\$450 million, and the net proceeds (after deducting the Managers’ commissions and other estimated expenses payable in connection with this offering) are approximately US\$445.5 million.

An application for the listing of the Bonds has been submitted to the Vienna Stock Exchange. Trading of the Bonds on the Vienna MTF operated by the Vienna Stock Exchange is expected to commence on or around July 30, 2026. The Company has obtained the approval for the listing of, and permission to deal in, the Conversion Shares on the Hong Kong Stock Exchange.

CSRC FILINGS

The Company will subsequently comply with CSRC Filing Rules and complete the CSRC Filings in connection with the issue of the Bonds.

EFFECT ON SHAREHOLDINGS AS A RESULT OF CONVERSION OF THE BONDS

The table below sets out a summary of the shareholdings (excluding treasury shares) in the Company (i) as at the date of this announcement and (ii) upon the exercise in full of the Conversion Rights attached to the Bonds:

Shareholders	As at the date of this announcement		Upon full conversion of the Bonds at the initial Conversion Price of HK\$5.55 per Class B Share	
	<i>Number of Shares</i>	<i>Approximate % of the total issued share capital</i>	<i>Number of Shares</i>	<i>Approximate % of the total issued share capital</i>
Dr. Kai Yu	1,805,545,220	12.39%	1,805,545,220	11.87%
Other Shareholders	12,766,177,965	87.61%	12,766,177,965	83.95%
Bondholders	—	—	635,635,135	4.18%
Total	14,571,723,185	100%	15,207,358,320	100%

Notes:

- As of the date of this announcement, Dr. Kai Yu was interested in (i) 1,724,127,376 Class A Shares, and (ii) 9,484,751 Class B Shares, held by Everest Robotics Limited. Everest Robotics Limited was held by Bigsur Robotics Limited as to 99% and Horizon Robotics, Inc. as to 1%. Horizon Robotics, Inc. was wholly-owned by Dr. Kai Yu. Bigsur Robotics Limited was wholly-owned by Trident Trust Company (HK) Limited as trustee of Rock Street Trust, the family trust established by Dr. Kai Yu (as settlor) for the benefit of Dr. Kai Yu and his family. In addition, Dr. Kai Yu was also interested in 71,933,093 Class B Shares pursuant to the share awards granted to him under the 2018 Share Incentive Plan.
- The aggregate of the percentage figures in the table above may not add up to the relevant sub-total or total percentage figures shown due to rounding of the percentage figures to two decimal places.
- Assuming that no other Shares are issued or repurchased by the Company.

By Order of the Board
Horizon Robotics
Dr. Kai Yu
Chairman and Executive Director

Hong Kong, July 29, 2026

As of the date of this announcement, the board of directors of the Company comprises (i) Dr. Kai Yu, Dr. Chang Huang, Dr. Jian Xu and Dr. Liming Chen as executive directors; (ii) Mr. Liang Li, Mr. Qin Liu, Dr. André Stoffels and Mr. Jianjun Zhang as non-executive directors; and (iii) Dr. Jun Pu, Mr. Yingqiu Wu, Dr. Katherine Rong Xin and Dr. Ya-Qin Zhang as independent non-executive directors.